Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
December 2022
-
Media Release
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
EC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free… -
Media Release
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH… -
Media Release
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus… -
Key Release
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been…
November 2022
-
Media Release
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
Novartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malariaThis novel combination also contains an… -
Media Release
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and… -
Media Release
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (… -
Media Release
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into…
October 2022
-
Key Release
Novartis maintains growth momentum and confirms FY’22 Group guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc),… -
Key Release
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T3 en hausse de +4% tcc1 (-4% USD) Innovative Medicines (IM) : hausse du chiffre d’affaires de +4% tcc (-3% USD),… -
Key Release
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im dritten Quartal um +4% kWk1 (–4% USD): Innovative Medicines (IM) steigerte den Umsatz um +4% kWk (–3% USD), getragen von… -
Key Release
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…